Clinical trials: Nonorganic Psychosis
Schizophrenia
A Trial of 15 and 30 mg Doses of CVL-231 (Emraclidine) in Participants With Schizophrenia
This is a Phase 2, multicenter, randomized, double-blind, placebo-controlled, parallel-group, 6-week trial to evaluate the efficacy, safety, and tolerability of 2 fixed doses of CVL-231 (Emraclidine) (15 mg QD and 30 mg QD) in…
- Trial name
- NCT05227703
- Testing
- Emraclidine 15 mg, Emraclidine 30 mg
- Where
- 26 sites in United States, Bulgaria and 1 more
- Volunteers
- 391 people
- Sponsor
- AbbVie
Schizophrenia, Schizophreniform Disorder
rTMS in First Episode Psychosis
This study proposes to examine the application of rTMS for the treatment of cognitive dysfunction in FEP. This is an important population for study because if effective, rTMS may represent a preventative treatment for the…
- Conditions
- Schizophrenia, Schizophreniform Disorder, Schizoaffective Disorder
- Trial name
- EmeraldThunder (NCT02131129)
- Testing
- rTMS
- Where
- 2 sites in United States
- Volunteers
- 20 people
- Sponsor
- Indiana University
Schizophrenia
Efficacy and Safety of Iloperidone Compared With Placebo and Active Control in Subjects With Acute Schizophrenia
The purpose of this study is to determine the safety and efficacy of iloperidone compared to placebo and an active comparator in the treatment of patients with schizophrenia in acute exacerbation.
- Trial name
- NCT00254202
- Testing
- Iloperidone, Ziprasidone
- Where
- 42 sites in United States, India
- Volunteers
- 593 people
- Sponsor
- Vanda Pharmaceuticals
Schizophrenia
Comparison of Aripiprazole and Risperidone for the Treatment of People With First-Episode Psychosis
This 52 week long study evaluates the effectiveness of aripiprazole versus risperidone in treating people with first-episode schizophrenia.
- Trial name
- NCT00320671
- Testing
- Aripiprazole, Risperidone
- Where
- United States
- Volunteers
- 198 people
- Sponsor
- Northwell Health
Schizophrenia, Schizophrenic Disorders
Open-label Study of Flexible-dose Paliperidone ER (Extended Release) to Treat Adolescent Schizophrenia.
The purpose of this open-label study is to evaluate the long-term (6-month) safety and tolerability of extended-release paliperidone, an atypical antipsychotic, given in flexible dosages to adolescents with schizophrenia.
- Conditions
- Schizophrenia, Schizophrenic Disorders, Psychotic Disorders, Dementia Praecox
- Trial name
- NCT00488319
- Testing
- Paliperidone ER
- Where
- 53 sites in United States, Belgium and 9 more
- Volunteers
- 400 people
- Sponsor
- Janssen Research & Development, LLC
Schizophrenia, Schizophreniform Disorder
Omega-3 Dietary Supplements in Schizophrenia
This 16-week placebo-control study looks to investigate whether patients with schizophrenia for two years or less may benefit from omega-3 supplements.
- Conditions
- Schizophrenia, Schizophreniform Disorder, Schizoaffective Disorder, Bipolar Disorder
- Trial name
- NCT01786239
- Testing
- Risperidone, Omega-3 capsules
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- Delbert Robinson
Psychotic Disorders
Facilitating Engagement in Evidence-Based Treatment for Early Psychosis
The purpose of this mixed methods study is to evaluate a peer-delivered decision support intervention with emerging adults newly enrolled in an early intervention program, also known as coordinated specialty care (CSC).
- Trial name
- NCT04532034
- Testing
- Peer-Delivered Decision Support Intervention
- Where
- 3 sites in United States
- Volunteers
- 12 people
- Sponsor
- Temple University
Psychotic Disorders
This Study Tests Whether BI 409306 Prevents Patients With a Specific Type of Mental Illness (Attenuated Psychosis Syndrome) From Becoming Worse. This Study Looks at How Well Patients Tolerate the Medicine and How Effective it is Over 1 Year
This is a study in people between 16 and 30 years of age who have a specific type of mental illness called attenuated psychosis syndrome (APS).
- Trial name
- NCT03230097
- Testing
- BI 409306
- Where
- 33 sites in United States, Canada and 2 more
- Volunteers
- 50 people
- Sponsor
- Boehringer Ingelheim
Schizophrenia, Bipolar Disorder
Multi-modal Assessment of Gamma-aminobutyric Acid (GABA) Function in Psychosis
The purpose of this study is to better understand mental illness and will test the hypotheses that, while viewing affective stimuli, patient groups will show increased blood oxygenation level dependent (BOLD) signal by fMRI after…
- Conditions
- Schizophrenia, Bipolar Disorder, Healthy, Psychosis
- Trial name
- GABAmech (NCT04004416)
- Testing
- Lorazepam and fMRI
- Where
- United States
- Volunteers
- 143 people, healthy volunteers welcome
- Sponsor
- University of Michigan
Alzheimer's Disease, Psychosis
Treatment of Psychosis and Agitation in Alzheimer's Disease
Clinically, many patients with AD show no response or minimal response to antipsychotics for symptoms of agitation/aggression or psychosis, or they have intolerable side effects on these medications.
- Conditions
- Alzheimer's Disease, Psychosis, Agitation
- Trial name
- NCT02129348
- Testing
- Lithium
- Where
- 4 sites in United States
- Volunteers
- 77 people
- Sponsor
- New York State Psychiatric Institute